https://www.selleckchem.com/pr....oducts/3-methyladeni
Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. The National Cancer Database from 2004 to 2016 was used. 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR 4.27 and 2.42; p0.0001 and 0.009) compared to community centers. Patients with stage
Like
Comment
Share
